Rochem International Inc Rochem International Inc

X
[{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Launches Global Clinical Trials for AI-based Sarcopenia Treatment","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"Oncocross","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oncocross Completes Phase I Global Clinical Trial of OC514, Treatment for Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Oncocross

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Oncocross is developing OC514 as a drug-drug combination product designed to prevent or treat sarcopenia and other rare muscular diseases, using Oncocross’ proprietary AI platform RAPTOR AI™.

            Lead Product(s): OC514

            Therapeutic Area: Musculoskeletal Product Name: OC514

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Oncocross obtained Australia’s TGA approval on phase I IND application for OC514, aims to evaluate the safety, pharmacokinetics, and pharmacodynamics for targeting muscular diseases including sarcopenia.

            Lead Product(s): OC514

            Therapeutic Area: Musculoskeletal Product Name: OC514

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY